Evaluating the Impact of a Polyherbal Formulation on Core Symptoms and Cognitive Function in Children with ADHD: An Open-Label Clinical Trial

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common childhood neurodevelopmental condition marked by inattention, hyperactivity, and impulsivity, often impairing academic and social functioning. While pharmacological treatments remain standard, they may not fully address the disorder's multifactorial nature and are often associated with side effects. Consequently, integrative approaches like herbal therapies are gaining attention. This study evaluates the clinical efficacy of a polyherbal formulation (PHF) in managing core and associated ADHD symptoms. A prospective open-label trial was conducted in 19 children (aged 3–12 years) diagnosed with ADHD, who received PHF for two months in age-specific doses, thrice daily. The formulation included Withania somnifera, Glycyrrhiza glabra, Rauvolfia serpentina, and Nardostachys jatamansi, prepared under GMP conditions. Outcome measures—ADHD Questionnaire (ADHD-Q), Vineland Social Maturity Scale (VSMS), Binet-Kamat Test of Intelligence (BKT-IQ), and Digit Span (Forward)—showed statistically significant improvements (p < .001) across all domains. These findings suggest PHF may offer a safe, well-tolerated, and cost-effective complementary option for managing pediatric ADHD.